Company Overview and News

4
Corvus Gold Closes $4.5M Financing with Strategic Investor to Advance Its Mother Lode Project Through 2019

2018-06-07 globenewswire
VANCOUVER, British Columbia, June 07, 2018 (GLOBE NEWSWIRE) -- Corvus Gold Inc. (“Corvus” or the “Company”) - (TSX:KOR) (OTCQX:CORVF) announces it has completed a CAD $4,500,002 private placement (the “Private Placement”). Pursuant to the Private Placement, the Company issued 1,730,770 common shares at a price of CAD $2.60 to a key strategic shareholder. No warrants were issued. Proceeds of the financing will fund the planned Phase Three 30,000 metre exploration drill program at Mother Lode project through 2018-19.
KOR CORVF

15
Renaissance Gold Drilling Update

2018-05-01 accesswire
VANCOUVER, BC / ACCESSWIRE / May 1, 2018 / Renaissance Gold Inc. TSX.V: REN ("RenGold" or the "Company") expects exploration drilling programs on at least seven of its partner-funded projects during 2018. Some of that drilling is ongoing and other programs are planned for later in the year. The following is an update on two of these projects already underway.
AULGF RNSGF KOR REN AU AGG S2R PSPGF CORVF

4
Corvus Gold Continues to Expand Deposit West, Drill Results Include 33.5 Metres @ 2.2 g/t Gold, Mother Lode Project, Nevada

2018-04-25 globenewswire
VANCOUVER, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) -- Corvus Gold Inc. (“Corvus” or the “Company”) - (TSX:KOR) (OTCQX:CORVF) announces it has received results from three stepout holes in the southwest extension of the Mother Lode deposit (Figure 1) highlighted by hole ML18-053 which returned 33.5m @ 2.2 g/t gold including 19.8m @ 3.3 g/t gold. Assay results returned encouraging intercepts showing continued expansion of the deposit which is nearly all oxide to the bottom of the holes (Table 1).
KOR CORVF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:KOR / Corvus Gold Inc on message board site Silicon Investor.

Akorn Inc. CDMA, Qualcomm, [Hong Kong, Korea, LA] THE MARKET TEST!
KERMu0027S KORNER Boycott China Until It Squeezes the North Korean Regime to r
Korea Telecom - KTC Amkor Technology Inc (AMKR)
Korea Korea Electric Power Corp.
KF: Korea Fund Far East Markets - Taiwan, Korea, Hong Kong, China and India